Drugs / Zilbrix™
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00158756 Comparator | Sep 2005 → Nov 2006 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zilbrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00158756 ↗ |
| Modality | Vaccine | “GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine” NCT00158756 ↗ |
| Route | Intramuscular | “intramuscularly into the right anterolateral thigh” NCT00158756 ↗ |